---
title: "Brain volume changes, cerebral microbleeds, and cognition in middle-aged adults with type 1 diabet"
id: "medrxiv-2-brain-volumes-and-their-relationship-with-cerebral-microbleeds-and-cognition-in"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-2-brain-volumes-and-their-relationship-with-cerebral-microbleeds-and-cognition-in"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.04.26359672v1?rss=1"
published_at: "2026-08-06T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Brain volume changes, cerebral microbleeds, and cognition in middle-aged adults with type 1 diabet
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-2-brain-volumes-and-their-relationship-with-cerebral-microbleeds-and-cognition-in
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.04.26359672v1?rss=1)
- **Published At:** 2026-08-06T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Adults with **type 1 diabetes** (n=163; mean age 46 ± 8 years; diabetes duration 31 ± 10 years; 53% women) and 48 matched controls underwent MRI and neuropsychological testing to assess brain volumes, cerebral microbleeds (CMBs), and cognition. - Volumetric measures adjusted for intracranial volume included **total brain volume (TBV)**, white matter volume (WMV), and regional volumes (cortex, thalamus, hippocampus, nucleus accumbens, choroid plexus). - Compared with controls, participants with type 1 diabetes had smaller **TBV**, **WMV**, and smaller cortex, thalamus, and nucleus accumbens volumes; they also had larger **choroid plexus** volumes (Cohen's d = 0.39–0.54). - Within the diabetes group, those with ≥3 **CMBs** had smaller TBV, WMV, cortex, thalamus, and nucleus accumbens volumes than those with 0–2 CMBs (Cohen's d = 0.54–0.92). - No direct associations were found between brain volumes and measures of processing speed or executive functions when considered alone. - Significant negative synergistic interactions were found between CMB burden and several volumetric measures (TBV, WMV, nucleus accumbens, choroid plexus) on processing speed and executive functions (standardized betas −0.61 to −0.51 and 0.54 to 0.75; FDR-corrected p = 0.006–0.048), indicating combined structural and vascular burden linked to worse cognition. - Study data are not publicly available due to consent restrictions; collaboration requests can be directed to the lead investigator. Ethical approval was provided by the Helsinki University Hospital ethics committee (HUS/3313/2018). - Competing interest disclosures were reported for several authors; many authors declared no competing interests.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=Rnuv7l7uDGD2GCxc8.7f_tBzj04m1rbdXj5gkpI4ct0-1786057998.3762333-1.2.1.1-X8IerDnNi0NfyVcJ_W6M2T7b1OY49LLmCSmPeW.ngjU) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.04.26359672v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Brain volumes and their relationship with cerebral microbleeds and cognition in middle-aged adults with type 1 diabetes [ View ORCID Profile](http://orcid.org/0000-0002-2063-8517)Iiris Kylaheiko, Linda Kuusela, Tor-bjorn Claesson, Aleksi Tarkkonen, Juha Martola, Teemu I. Paajanen, Jussi Virkkala, Per-Henrik Groop, Lena M. Thorn, Turgut Tatlisumak, [ View ORCID Profile](http://orcid.org/0000-0002-6630-6104)Jukka Putaala, [ View ORCID Profile](http://orcid.org/0000-0003-1494-8292)Daniel Gordin, [ View ORCID Profile](http://orcid.org/0000-0001-7889-1120)Hanna Jokinen, FinnDiane Study Group doi: https://doi.org/10.64898/2026.08.04.26359672 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Iiris Kylaheiko 1 Department of Psychology, Faculty of Medicine, University of Helsinki, Helsinki, Finland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Iiris%2BKylaheiko%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kylaheiko%20I&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AIiris%2BKylaheiko%2B) * [ORCID record for Iiris Kylaheiko](http://orcid.org/0000-0002-2063-8517 "Open in new tab") Linda Kuusela 2 HUS Medical Imaging Center, Department of Radiology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Linda%2BKuusela%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kuusela%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALinda%2BKuusela%2B) Tor-bjorn Claesson 2 HUS Medical Imaging Center, Department of Radiology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tor-bjorn%2BClaesson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Claesson%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATor-bjorn%2BClaesson%2B) Aleksi Tarkkonen 2 HUS Medical Imaging Center, Department of Radiology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Aleksi%2BTarkkonen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tarkkonen%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAleksi%2BTarkkonen%2B) Juha Martola 2 HUS Medical Imaging Center, Department of Radiology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Juha%2BMartola%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Martola%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJuha%2BMartola%2B) Teemu I. Paajanen 3 Occupational Health Unit, Finnish Institute of Occupational Health, Helsinki, Finland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Teemu%2BI.%2BPaajanen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Paajanen%20TI&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATeemu%2BI.%2BPaajanen%2B) Jussi Virkkala 4 Department of Clinical Neurophysiology, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jussi%2BVirkkala%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Virkkala%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJussi%2BVirkkala%2B) Per-Henrik Groop 5 Department of Nephrology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Per-Henrik%2BGroop%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Groop%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APer-Henrik%2BGroop%2B) Lena M. Thorn 6 Department of General Practice and Primary Health Care, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lena%2BM.%2BThorn%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Thorn%20LM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALena%2BM.%2BThorn%2B) Turgut Tatlisumak 7 Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Turgut%2BTatlisumak%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tatlisumak%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATurgut%2BTatlisumak%2B) Jukka Putaala 8 Department of Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jukka%2BPutaala%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Putaala%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJukka%2BPutaala%2B) * [ORCID record for Jukka Putaala](http://orcid.org/0000-0002-6630-6104 "Open in new tab") Daniel Gordin 5 Department of Nephrology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Daniel%2BGordin%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Gordin%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADaniel%2BGordin%2B) * [ORCID record for Daniel Gordin](http://orcid.org/0000-0003-1494-8292 "Open in new tab") Hanna Jokinen 9 Division of Neuropsychology, HUS Neurocenter, Helsinki University Hospital and University of Helsinki, Helsinki, Finland * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hanna%2BJokinen%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Jokinen%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHanna%2BJokinen%2B) * [ORCID record for Hanna Jokinen](http://orcid.org/0000-0001-7889-1120 "Open in new tab") * For correspondence: hanna.jokinen@helsinki.fi * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.04.26359672v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1273609/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.04.26359672v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1273609/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.04.26359672v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1273609/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.08.04.26359672v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1273609/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.04.26359672v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1273609/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.04.26359672v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1273609/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Objective: Type 1 diabetes is related to an increased risk of structural brain alterations, cerebral microbleeds (CMBs), and cognitive deficits. We explored brain volumes and their direct and combined associations with CMBs on cognitive performance in middle-aged individuals with type 1 diabetes. Research Design and Methods: Adults with type 1 diabetes (n=163; mean age 46+/-8 years; diabetes duration 31+/-10 years; 53% women) and 48 matched controls underwent brain MRI and clinical and neuropsychological evaluations. Volumetric MRI measures adjusted to intracranial volume included total brain volume (TBV), white matter volume (WMV), and total volumes of cortex, thalamus, hippocampus, nucleus accumbens, and choroid plexus. Results: Individuals with type 1 diabetes had smaller TBV, WMV, and volumes of cortex, thalamus, and nucleus accumbens, and larger choroid plexus compared to controls (Cohen d=0.39-0.54). Those with type 1 diabetes and 3 or more CMBs had smaller TBV, WMV, and volumes of cortex, thalamus, and nucleus accumbens, compared to those with 0-2 CMBs (Cohen d=0.54-0.92). We found no direct associations between brain volumes and processing speed or executive functions. However, TBV, WMV, nucleus accumbens, and choroid plexus volumes had significant negative synergistic interactions with CMBs on processing speed and executive functions (standardized betas: -0.61 to -0.51 and 0.54 to 0.75, FDR-corrected p=0.006-0.048). Conclusions: Smaller global and regional brain volumes and larger choroid plexus volumes were found in middle-aged individuals with type 1 diabetes compared to healthy controls. Together with CMB burden, structural brain volumetric alterations were associated with accelerated cognitive deficits. ### Competing Interest Statement IK, LK, T-BC, JM, TIP, JV, LMT, and HJ report no competing interests. AT is a shareholder and co-founder of RokoteNyt Oy. P-HG has received investigator-initiated research grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Cebix. Eli Lilly, Janssen, Medscap, Merck Sharp & Dohme, Mundipharma, Nestle, Novartis, Novo Nordisk, and Sanofi; and has received lecture fees from Astellas, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Merck Sharp&Dohme, Medscape, Menarini, Novartis, Novo Nordisk, PeerVoice, Sanofi, and Sciarc. TT is serving/has served as an advisory board member to Bayer, Bristol Myers Squibb, Eli Lilly, Inventiva, and Portola Pharma, and received lecture honorarium from Argenx. JP reports Lecture or Advisory Board honoraria from Novo Nordisk, Bayer, KRKA, and AstraZeneca, and research funding from Bayer and Amgen. DG reports Lecture, Advisory Board, or Steering Committee Honoraria from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Cogentia Healthcare Consulting Ltd, Fresenius, GE Healthcare, Harald AI, Novo Nordisk, and Ratiopharm. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The ethics committee of Helsinki University Hospital gave ethical approval for this work (HUS/3313/2018). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability Individual-level data from the study participants are not publicly available due to consent restrictions provided by the participants at the time of data collection. Readers may propose collaboration to access the individual-level data by contacting the lead investigator. ## Funder Information Declared Folkhälsan Research Foundation Wilhelm and Else Stockmann Foundation Liv och Hälsa Society Sigrid Jusélius Foundation, 220027 Medical Society of Finland ate funding for University-level Health Research by Helsinki University Hospital, TYH2023403, TYH2021206 Kymenlaakso Regional Fund Diabetes Research Foundation Ministry of Social Affairs and Health/Kymenlaakso Central Hospital, 500393, 500420 University of Helsinki Minerva Foundation Institute for Medical Research Research Council of Finland, UAK1021MRI, UAK2112JOK Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.04.26359672v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.07.15.26357456v2 "Implementation of a standardized Video-based Asynchronous Neurological Examination \(VANE\) in a multi-center observational study of Alzheimer's disease \(AD\) and AD related dementias")[Next ](https://www.medrxiv.org/content/10.64898/2025.11.28.25340407v2 "Rising resistance to linezolid among critically ill patients calls for model-informed precision dosing in the empirical setting") Posted August 06, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.04.26359672v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/06/2026.08.04.26359672.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.04.26359672v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.08.04.26359672v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/06/2026.08.04.26359672.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Brain volumes and their relationship with cerebral microbleeds and cognition in middle-aged adults with type 1 diabetes Iiris Kylaheiko, Linda Kuusela, Tor-bjorn Claesson, Aleksi Tarkkonen, Juha Martola, Teemu I. Paajanen, Jussi Virkkala, Per-Henrik Groop, Lena M. Thorn, Turgut Tatlisumak, Jukka Putaala, Daniel Gordin, Hanna Jokinen, FinnDiane Study Group medRxiv 2026.08.04.26359672; doi: https://doi.org/10.64898/2026.08.04.26359672 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.04.26359672v1%26text%3DBrain%2520volumes%2520and%2520their%2520relationship%2520with%2520cerebral%2520microbleeds%2520and%2520cognition%2520in%2520middle-aged%2520adults%2520with%2520type%25201%2520diabetes "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.04.26359672v1%26t%3DBrain%2520volumes%2520and%2520their%2520relationship%2520with%2520cerebral%2520microbleeds%2520and%2520cognition%2520in%2520middle-aged%2520adults%2520with%2520type%25201%2520diabetes "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medr
## Related Clinical Research

- [Antidiabetic regimens and risk of cognitive disorders in type 2 diabetes: large retrospective coho](https://medichelpline.com/clinical-feed/plos-one-23-antidiabetic-medications-and-risk-of-cognitive-disorders-in-type-2-diabetes-a.md)
- [Type 1 Diabetes Linked to Higher Dementia Risk in Large U.S. Study](https://medichelpline.com/clinical-feed/medical-news-today-27-type-1-diabetes-linked-to-significantly-higher-dementia-risk-large-u-s-study-finds.md)
- [After Ultragenyx Angelman drug failure, experts say other antisense therapies still hold promise](https://medichelpline.com/clinical-feed/stat-news-1-stat-after-failure-of-angelman-syndrome-drug-experts-see-hope-in-other.md)
- [Episodic Memory and Functional Tests Best Predict 24‑Month MCI → Alzheimer’s Progression in ADNI C](https://medichelpline.com/clinical-feed/medrxiv-13-comparative-value-of-cognitive-and-functional-assessments-for-predicting-24.md)
- [SniffCell: Cell-type-resolved somatic variant discovery from bulk long-read sequencing](https://medichelpline.com/clinical-feed/medrxiv-11-cell-type-resolved-somatic-variant-discovery-from-bulk-long-read-sequencing.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.